Joel Poder

1.4K posts

Joel Poder

Joel Poder

@JPoderMedPhys

Medical Physicist at St George Cancer Center, Sydney. Special interest in brachytherapy. Opinions are my own and not the views of my employer

Sydney, New South Wales 参加日 Eylül 2019
420 フォロー中599 フォロワー
Joel Poder
Joel Poder@JPoderMedPhys·
@cristian_udo @ndesai2005 @DrAndrewLoblaw Absolutely, apologies if previous posts have come across as rude. No mean feat to follow these patients for 10 years. For me, shows lack of long term HDR brachy data in multi-institutional setting. We need to follow your lead and do better!
English
1
0
2
35
Joel Poder
Joel Poder@JPoderMedPhys·
Congratulations @cristian_udo and co-authors on putting this together. Hard to take too much away given the differences in how toxicity was collected amongst SBRT studies and only 1 brachytherapy trial included from single site. We need more data before making conclusions
Dr. Andrew Loblaw@DrAndrewLoblaw

Curious about whether #SBRT or #brachy is better treatment for intermediate risk prostate cancer? See @cristian_udo @JAMANetworkOpen article just posted! JAMANetworkOpen.2026;9(2):e260146. doi:10.1001/jamanetworkopen.2026.0146 @DrSpratticus @AmarUKishan @nickva1 @alison_tree

English
2
1
5
3K
Joel Poder
Joel Poder@JPoderMedPhys·
@DrAndrewLoblaw Sunnybrook are world leaders in brachy. Have paved the way in multiple aspects
English
0
0
1
955
Dr. Andrew Loblaw
Dr. Andrew Loblaw@DrAndrewLoblaw·
/2 Specially trained Med Phys and MRTs Excellent leadership: Dr Morton - Received Ulrich Henschke Award (ABS, 2025) for lifetime achievement - Head of brachytherapy QA for NRG 0815 and 0924 - Co-PI for CCTG PR19 - Co-RTQA lead for CCTG PR24
Dr. Andrew Loblaw@DrAndrewLoblaw

I think we do great #brachy. Here are the facts. Please judge for yourself! Mature program: LDR started in 1998, HDR (2001), Oncentra (2009) RTQA in 100% of cases (<0.5% minor dev'n rate) High volume centre: up to 400 PC patients / yr; 4-5 brachy physicians, dedicated OR ../2

English
1
3
9
1.2K
Daniel E Spratt
Daniel E Spratt@DrSpratticus·
Amazing to see the continued results of the collaboration w/ @AmarUKishan from @UCLA and UH Seidman @RadOncUH and trial groups and brilliant collaborators around the world. Dozens of high impact practice changing studies, and POSEIDON published in @TheLancet today is one more.
Daniel E Spratt tweet media
Daniel E Spratt@DrSpratticus

#GU26 @TheLancet Extremely proud to co-lead with @AmarUKishan and all investigators in MARCAP for helping make these exciting results possible. Presents POSEIDON assessing use of hormone therapy use and duration with post-op RT for recurrent PCa: An individual patient data meta-analysis of 6 trials thelancet.com/journals/lance… @ASCO

English
1
4
27
2.7K
Joel Poder
Joel Poder@JPoderMedPhys·
@EvanThomas84 @cristian_udo 🤣 your reference is almost wasted on an Australian born in the late 80s. It’s definitely hypothesis generating but as the authors point out in the manuscript there a number of methodological aspects that should be considered before people close the door on brachy here.
English
1
0
1
115
Evan Thomas MD/PhD
Evan Thomas MD/PhD@EvanThomas84·
@JPoderMedPhys @cristian_udo Hard to take too much away? Seems like this is more one sided than ‘91 Operation Desert Storm. IMO, you can’t get a marginal dose with HDR high enough in one (or two) fractions without nuking urethra and bladder base.
English
1
0
8
468
Todd Scarbrough
Todd Scarbrough@toddscarbrough·
@jaguaranna27 @JoeChangMD IMHO anyone with an IGRT/IMRT capable linac should be cranially radiosurgerizing “non complex” CNS mets; and almost all rural/community centers have such linacs nowadays
English
1
0
1
31

ディスカバー

@cristian_udo @ndesai2005 @DrAndrewLoblaw @MellyB_7 @DrewMoghanaki @TheASMR1 @DrSpratticus @johndavid_JDMD